Hypersensitivity and Allergic Drug Reactions

Hypersensitivity drug reactions are immune-mediated adverse reactions that range from urticaria and anaphylaxis to severe delayed skin reactions. They are a major subset of Type B (bizarre) reactions, are not predictable from a drug's principal pharmacology, and are classically organised by the Gell and Coombs immune mechanisms. Some are now linked to specific genetic markers, bringing immunology and pharmacogenomics together.

Definition

Drug hypersensitivity reactions are adverse drug reactions that result from a specific immunological response to a drug or its metabolites, clinically resembling allergy and including both immediate IgE-mediated and delayed T-cell-mediated mechanisms.

Scope

The topic covers the immunological classification of drug hypersensitivity, the distinction between immediate (IgE-mediated) and delayed (T-cell-mediated) reactions, the spectrum of severe cutaneous adverse reactions, and the genetic associations that predispose to specific reactions. It is a reference and educational entry describing mechanisms and recognition, not a guide to diagnosis or treatment.

Core questions

• How do immediate and delayed hypersensitivity reactions differ in mechanism and timing?
• How does the Gell and Coombs framework classify these reactions?
• What are the severe cutaneous adverse reactions and why are they dangerous?
• How do genetic markers such as HLA alleles predispose to specific drug hypersensitivities?

Key concepts

• Immediate (Type I, IgE-mediated) reactions
• Delayed (Type IV, T-cell-mediated) reactions
• Gell and Coombs classification
• Hapten and pro-hapten concepts
• p-i concept (pharmacological interaction with immune receptors)
• Severe cutaneous adverse reactions (SJS/TEN, DRESS)
• HLA-associated hypersensitivity
• Anaphylaxis

Mechanisms

Drug hypersensitivity reactions are sorted by immune mechanism. In the Gell and Coombs scheme, immediate reactions are typically Type I, mediated by drug-specific IgE that triggers mast-cell degranulation and can cause urticaria or anaphylaxis within minutes to hours; delayed reactions are predominantly Type IV, mediated by T cells and producing maculopapular eruptions or the severe cutaneous syndromes (Pichler, 2007). Drugs may engage the immune system as haptens that bind proteins, or, as the p-i concept proposes, by interacting directly and non-covalently with immune receptors. Because these reactions reflect specific immune recognition rather than augmented pharmacology, they fall outside the dose-dependent, predictable category (Edwards & Aronson, 2000).

Clinical relevance

Recognising the pattern and timing of a suspected hypersensitivity reaction helps distinguish benign rashes from life-threatening syndromes, and genetic screening can identify individuals at high risk before exposure -- HLA-B*57:01 screening sharply reduces abacavir hypersensitivity (Mallal et al., 2008). This entry describes mechanisms and risk markers as reference knowledge and does not provide diagnostic or treatment instructions.

Epidemiology

Hypersensitivity reactions form a notable share of immune-mediated adverse drug reactions; the severe cutaneous syndromes are rare but carry high morbidity and mortality. The strength of HLA associations varies by drug and by ancestry, which is why some screening recommendations are population-specific (Mallal et al., 2008).

Evidence & guidelines

Classification of drug hypersensitivity rests on immunological scholarship building on the Gell and Coombs framework (Pichler, 2007). Genetic prediction is supported by randomised evidence for HLA-B*57:01 and abacavir (Mallal et al., 2008), which underpins pharmacogenomic screening recommendations for that drug.

History

The Gell and Coombs scheme, introduced in the 1960s, gave immunology its enduring four-type classification of hypersensitivity, which was adapted to drug reactions. Pichler later refined the delayed (Type IV) category into subtypes by effector cell and cytokine profile and articulated the p-i concept (Pichler, 2007). The 2008 PREDICT-1 trial demonstrated that prospective HLA-B*57:01 screening could prevent abacavir hypersensitivity, a landmark for immunogenetic prediction (Mallal et al., 2008).

Debates

Are drugs recognised only as protein-bound haptens, or can they engage immune receptors directly?

The classical hapten model holds that small drugs must bind proteins to become immunogenic, but the p-i concept argues some drugs interact directly and reversibly with T-cell or HLA receptors; both mechanisms appear to operate depending on the drug.

Key figures

• Werner J. Pichler
• Philip G. H. Gell
• Robin R. A. Coombs
• Simon Mallal
• Elizabeth Phillips

Seminal works

• pichler-2007
• mallal-2008

Frequently asked questions

Is every drug rash an allergic reaction?

No. Many drug-related rashes are not immunologically mediated, and some hypersensitivity-like reactions occur without a classic allergy mechanism. True drug hypersensitivity requires a specific immune response, which is why pattern, timing, and sometimes testing are used to characterise a reaction.

What is the difference between immediate and delayed hypersensitivity?

Immediate reactions are usually IgE-mediated (Gell and Coombs Type I) and appear within minutes to a few hours, potentially as urticaria or anaphylaxis. Delayed reactions are mainly T-cell-mediated (Type IV) and develop over hours to days, including maculopapular eruptions and severe cutaneous syndromes.